HOME HELP FEEDBACK TABLE OF CONTENTS ARCHIVE SUBSCRIPTIONS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Avilés, A. Articles by Jesús Nambo, M. Search for Related Content PubMed PubMed Citation Articles by Avilés, A. Articles by Jesús Nambo, M.

Rituximab and dose dense chemotherapy in primary breast lymphoma

^* Oncology Research Unit;
^° Department of Hematology, Oncology Hospital, National Medical Center, IMSS, México, D.F

Correspondence: Agustin Avilés MD, Plaza Luis Cabrera 5-502, Colonia Roma, 06700, México, D.F. Mexico. Phone: international +52.55.56276959. E-mail: agustin.aviles{at}imss.gob.mx

Treatment of primary breast lymphoma (PBL) remains unsatisfactory. We assess a clinical study to evaluate efficacy and toxicity of a dose dense regimen (CEOP-14) and rituximab in 32 previously untreated female patients with PBL in early stage. There was no difference in complete response rate (87%), event free-survival (75%) and overall survival (63%) compared with historical patients.

Key words: rituximab, chemotherapy, primary breast lymphoma.

This article has been cited by other articles:

				A. Aviles Breast lymphoma Ann. Onc., July 1, 2008; 19(7): 1360 - 1360. [Full Text] [PDF]